GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NovoCure Ltd (FRA:038) » Definitions » Cyclically Adjusted Revenue per Share

NovoCure (FRA:038) Cyclically Adjusted Revenue per Share : €3.87 (As of Mar. 2025)


View and export this data going back to 2015. Start your Free Trial

What is NovoCure Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

NovoCure's adjusted revenue per share for the three months ended in Mar. 2025 was €1.300. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €3.87 for the trailing ten years ended in Mar. 2025.

During the past 12 months, NovoCure's average Cyclically Adjusted Revenue Growth Rate was 15.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2025-05-21), NovoCure's current stock price is €15.21. NovoCure's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was €3.87. NovoCure's Cyclically Adjusted PS Ratio of today is 3.93.

During the past 12 years, the highest Cyclically Adjusted PS Ratio of NovoCure was 8.72. The lowest was 3.35. And the median was 4.87.


NovoCure Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for NovoCure's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NovoCure Cyclically Adjusted Revenue per Share Chart

NovoCure Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 3.83

NovoCure Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.26 3.51 3.39 3.83 3.87

Competitive Comparison of NovoCure's Cyclically Adjusted Revenue per Share

For the Medical Devices subindustry, NovoCure's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NovoCure's Cyclically Adjusted PS Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, NovoCure's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where NovoCure's Cyclically Adjusted PS Ratio falls into.


;
;

NovoCure Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, NovoCure's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=1.3/134.9266*134.9266
=1.300

Current CPI (Mar. 2025) = 134.9266.

NovoCure Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 0.071 100.684 0.095
201509 0.096 100.392 0.129
201512 0.136 99.792 0.184
201603 0.139 100.470 0.187
201606 0.187 101.688 0.248
201609 0.225 101.861 0.298
201612 0.330 101.863 0.437
201703 0.373 102.862 0.489
201706 0.387 103.349 0.505
201709 0.472 104.136 0.612
201712 0.507 104.011 0.658
201803 0.470 105.290 0.602
201806 0.577 106.317 0.732
201809 0.597 106.507 0.756
201812 0.658 105.998 0.838
201903 0.684 107.251 0.861
201906 0.796 108.070 0.994
201909 0.777 108.329 0.968
201912 0.899 108.420 1.119
202003 0.852 108.902 1.056
202006 0.956 108.767 1.186
202009 1.037 109.815 1.274
202012 1.064 109.897 1.306
202103 1.102 111.754 1.330
202106 1.071 114.631 1.261
202109 1.095 115.734 1.277
202112 1.135 117.630 1.302
202203 1.199 121.301 1.334
202206 1.274 125.017 1.375
202209 1.261 125.227 1.359
202212 1.155 125.222 1.245
202303 1.080 127.348 1.144
202306 1.095 128.729 1.148
202309 1.117 129.860 1.161
202312 1.148 129.419 1.197
202403 1.188 131.776 1.216
202406 1.297 132.554 1.320
202409 1.291 133.029 1.309
202412 1.422 133.157 1.441
202503 1.300 134.927 1.300

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


NovoCure  (FRA:038) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

NovoCure's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=15.21/3.87
=3.93

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 12 years, the highest Cyclically Adjusted PS Ratio of NovoCure was 8.72. The lowest was 3.35. And the median was 4.87.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


NovoCure Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of NovoCure's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


NovoCure Business Description

Industry
Traded in Other Exchanges
Address
Grenville Street, No. 4 The Forum, Second Floor, St. Helier, JEY, JE2 4UF
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.

NovoCure Headlines

No Headlines